Celiac disease and drug absorption: Implications for cardiovascular therapeutics

Introduction Current prevalence of celiac disease is estimated to be around 1 in the general population of Europe [1] and the United States [2]. Cardiovascular disease has an even higher prevalence and is the leading cause of death in these regions, causing 46 of all deaths in the European Union [3] and 32 in the United States [4]. Given that many cardiovascular drugs are orally administered, absorption of these drugs may be significantly altered in celiac disease.